ENGOT-OV24-NSGO/AVANOVA, EudraCT number: 2014-004269-26, Version 2.0
Part 2: AVANOVA2 – A three-arm, open-label, phase II randomized study to evaluate the efficacy of niraparib and/or niraparib-bevacizumab combination against bevacizumab alone in Women with HRD platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
FANDANGO – more details upcoming
ENGOT-EN1/FANDANGO, EudraCT number: 2016–000193-38, Version 1.3
A randomised phase II trial of first-line combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer.
PALEO – more details upcoming
ENGOT-EN3-NSGO/PALEO, EudraCT number: 2016-001848-20, Version 1.0
A randomized phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.